Paratek Pharmaceuticals (Paratek Pharmaceuticals) Short Interest

View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Paratek Pharmaceuticals's Short Interest

For the Biotechnology subindustry, Paratek Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paratek Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Short Interest falls into.

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Executives

Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson	director	AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz	director	C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh	director, officer: CEO	75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel	officer: CLO, General Counsel & Sec.	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow	officer: President & Chief Commercial	C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner	officer: Chief Development & Regulatory	C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie	director	101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann	director	LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham	director, officer: Exec. Chairman of the Board	890 WINTER STREET, WALTHAM MA 02451
James D Dondero	10 percent owner	300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan	officer: Chief Financial Officer	75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199